Patents by Inventor Mahmoud Rashed

Mahmoud Rashed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridinyl and pyrazinyl-(asa)indolsulfonamides
    Patent number: 11939319
    Abstract: The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: March 26, 2024
    Assignee: UCB PHARMA GMBH
    Inventors: Cecile Pegurier, Laurent Provins, Alvaro Cardenas, Marie Ledecq, Christa E. Mueller, Joerg Hockemeyer, Ali El-Tayeb, Nader Boshta, Mahmoud Rashed
  • N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis
    Publication number: 20220298112
    Abstract: Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.
    Type: Application
    Filed: June 16, 2020
    Publication date: September 22, 2022
    Inventors: Cécile Pegurier, Silvia Lovera, Christa E. Mueller, Joerg Hockemeyer, Mahmoud Rashed, Ali El-Tayeb, Yong-Qiang Zhang
  • Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides
    Publication number: 20210206749
    Abstract: The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.
    Type: Application
    Filed: June 18, 2019
    Publication date: July 8, 2021
    Inventors: Cecile Pegurier, Laurent Provins, Alvaro Cardenas, Marie Ledecq, Christa E. Mueller, Joerg Hockemeyer, Ali El-Tayeb, Nader Boshta, Mahmoud Rashed